Literature DB >> 12700468

Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy.

Tamara L Fisk1, Hui-Ming Hon, Jeffrey L Lennox, C Fordham von Reyn, C Robert Horsburgh.   

Abstract

This cross-sectional study of 110 individuals examined skin testing for latent tuberculosis infection (LTBI) after the initiation of highly active antiretroviral therapy. Skin test reactivity to one or more of four antigens was found in 98 out of 110 subjects (89%), and was maximal in those whose CD4 cell counts recovered to >= 100 cells/mm3. Skin testing is reliable for the identification or exclusion of LTBI once the CD4 cell count recovers to >= 100 cells/mm3.

Entities:  

Mesh：

Year:  2003        PMID： 12700468     DOI： 10.1097/00002030-200305020-00027

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  17 in total

1.  Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.

Authors:  Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir
Journal:  Am J Respir Crit Care Med       Date:  2007-01-11       Impact factor: 21.405

2.  Tuberculin skin test conversion and reactivity rates among adults with and without human immunodeficiency virus in urban settings in Ethiopia.

Authors:  Belete Tegbaru; Dawit Wolday; Tsehaynesh Messele; Mengistu Legesse; Yared Mekonnen; Frank Miedema; Debbie van Baarle
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Incidence and correlates of tuberculosis IGRA conversion among HIV-infected postpartum women.

Authors:  S Jonnalagadda; S M LaCourse; P Otieno; B Lohman-Payne; E Maleche-Obimbo; L M Cranmer; G C John-Stewart
Journal:  Int J Tuberc Lung Dis       Date:  2015-07       Impact factor: 2.373

4.  Validity of a self-reported history of a positive tuberculin skin test. A prospective study of drug users.

Authors:  Hillary V Kunins; Andrea A Howard; Robert S Klein; Julia H Arnsten; Alain H Litwin; Ellie E Schoenbaum; Marc N Gourevitch
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

5.  Performance of QuantiFERON-TB Gold test compared to tuberculin skin test in detecting latent tuberculosis infection in HIV- positive individuals in Iran.

Authors:  Masoud Mardani; Payam Tabarsi; Zohre Mohammadtaheri; Ehsan Chitsaz; Banafsheh Farokhzad; Fatemeh Hadavand; Latif Gachkar; Kambiz Nemati; Mohammad R Masjedi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

6.  Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity.

Authors:  Peter J Dodd; Kerry A Millington; Azra C Ghani; Junior Mutsvangwa; Anthony E Butterworth; Ajit Lalvani; Elizabeth L Corbett
Journal:  Am J Epidemiol       Date:  2010-04-09       Impact factor: 4.897

7.  Mycobacterium tuberculosis osteomyelitis in a patient with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): a case report.

Authors:  Supriya Mannepalli; Levonne Mitchell-Samon; Nilmarie Guzman; Manish Relan; Yvette S McCarter
Journal:  Cases J       Date:  2010-02-23

8.  Potentially preventable tuberculosis among HIV-infected persons in the era of highly active antiretroviral treatment.

Authors:  A C Pettit; G Barkanic; S Stinnette; P Rebeiro; R Blackwell; S P Raffanti; B E Shepherd; T R Sterling
Journal:  Int J Tuberc Lung Dis       Date:  2009-03       Impact factor: 2.373

9.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.

Authors:  Molebogeng X Rangaka; Robert J Wilkinson; Andrew Boulle; Judith R Glynn; Katherine Fielding; Gilles van Cutsem; Katalin A Wilkinson; Rene Goliath; Shaheed Mathee; Eric Goemaere; Gary Maartens
Journal:  Lancet       Date:  2014-05-13       Impact factor: 79.321

10.  Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals.

Authors:  Naasha J Talati; Ulrich Seybold; Bianca Humphrey; Abiola Aina; Jane Tapia; Paul Weinfurter; Rachel Albalak; Henry M Blumberg
Journal:  BMC Infect Dis       Date:  2009-02-10       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.